Screening the Effectiveness of Kabasura Kudineer against COVID 19 and Immune Proteins in Humans: In silico

Coronaviruses Pub Date : 2023-12-11 DOI:10.2174/0126667975281429231206073959

Architha Vijayalakshmi, Hemalatha S

{"title":"Screening the Effectiveness of Kabasura Kudineer against COVID 19 and\nImmune Proteins in Humans: In silico","authors":"Architha Vijayalakshmi, Hemalatha S","doi":"10.2174/0126667975281429231206073959","DOIUrl":null,"url":null,"abstract":"\n\nThe advent of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) triggered a pandemic known as coronavirus disease 2019 (COVID-19) in the twenty-first\ncentury. Recent research has revealed several details about SARS-CoV-2 pathogenesis, which has\ngreatly boosted research on COVID-19 vaccines and therapy methods for all the COVID variants.\nHowever, significant doubts about its treatment persist due to its fast mutating capability and its resistance to various drugs administered. Thus, there is a need for a cure to treat all the variants and\ntheir side effects.\n\n\n\nThe main aim of this study is to check 1) the effectiveness of Kabasura Kudineer against\nCOVID 19 2) the side effects of Kabasura Kudineer with the help of immune proteins in humans\n\n\n\nThe molecular docking was carried out between SARS-CoV-2 proteins and immune proteins in humans against Kabasura Kudineer compounds. The ADMET was also carried out to check\nthe Pharmacokinetics.\n\n\n\nThe results showed that chebulagic acid from Terminalia chebula has good binding capability with all the chosen targets1. The drug likeliness screening also proved it a good drug candidate.\n\n\n\nSiddha way of treatment has popped out which has been traditionally used for the\ntreatment of viral respiratory infections. The formulation called Kabasura Kudineer has been proven\nto have antiviral agents and compounds that boost the immune system\n","PeriodicalId":10815,"journal":{"name":"Coronaviruses","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Coronaviruses","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0126667975281429231206073959","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

The advent of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) triggered a pandemic known as coronavirus disease 2019 (COVID-19) in the twenty-first century. Recent research has revealed several details about SARS-CoV-2 pathogenesis, which has greatly boosted research on COVID-19 vaccines and therapy methods for all the COVID variants. However, significant doubts about its treatment persist due to its fast mutating capability and its resistance to various drugs administered. Thus, there is a need for a cure to treat all the variants and their side effects. The main aim of this study is to check 1) the effectiveness of Kabasura Kudineer against COVID 19 2) the side effects of Kabasura Kudineer with the help of immune proteins in humans The molecular docking was carried out between SARS-CoV-2 proteins and immune proteins in humans against Kabasura Kudineer compounds. The ADMET was also carried out to check the Pharmacokinetics. The results showed that chebulagic acid from Terminalia chebula has good binding capability with all the chosen targets1. The drug likeliness screening also proved it a good drug candidate. Siddha way of treatment has popped out which has been traditionally used for the treatment of viral respiratory infections. The formulation called Kabasura Kudineer has been proven to have antiviral agents and compounds that boost the immune system

查看原文本刊更多论文

筛选 Kabasura Kudineer 对 COVID 19 和人体免疫蛋白的有效性：硅学

严重急性呼吸系统综合征冠状病毒 2（SARSCoV-2）的出现引发了 21 世纪冠状病毒病 2019（COVID-19）的大流行。最近的研究揭示了 SARS-CoV-2 发病机制的一些细节，极大地推动了 COVID-19 疫苗和所有 COVID 变种治疗方法的研究。本研究的主要目的是检测 1) Kabasura Kudineer 对 COVID 19 的有效性 2) Kabasura Kudineer 在人体免疫蛋白的帮助下产生的副作用。结果表明，来自诃子树的诃子酸与所有选定的靶标都有很好的结合能力1。结果表明，从诃子中提取的诃子酸与所有选定的靶点都有很好的结合能力1，药物相似性筛选也证明它是一种很好的候选药物。被称为 Kabasura Kudineer 的配方已被证明具有抗病毒剂和增强免疫系统的化合物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Coronaviruses

CiteScore

1.50

自引率

0.00%

发文量